Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
Epistemonikos ID: ed3fa06c465adf76262451a787d90f1610feba47
First added on: May 11, 2024